CClinicalTrials.gg
CompletedNCT06686953Updated Nov 13, 2024

The Effect of Environmental Pollution on Colorectal Cancer

An observational study in Colorectal Carcinoma, sponsored by Dong Peng. Completed. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-11-13.

Sponsored by Dong Peng · Observational

Study type
Observational
Model
Cohort
Time perspective
Retrospective
Enrollment
6,300
Ages
18 Years and older
Sex
All
01

Study summary

Colorectal cancer (CRC) is one of the most common malignancies worldwide, and its main risk factors include age, genetic factors, inflammatory bowel diseases (e.g., ulcerative colitis and Crohn's disease), unhealthy diets (e.g., high-fat, low-fibre diets), obesity, physical inactivity, smoking, and excessive alcohol consumption. The relationship between environmental pollution and colorectal cancer has received increasing attention in recent years. Studies have shown that long-term exposure to fine particulate matter in the air, such as passive smoking, soot and oil smoke exposure, incense burning exposure, occupational exposure and outdoor work, PM2.5, PM10 and NO2 may increase the risk of colorectal cancer. These particulate matter can enter the lungs through breathing and trigger a chronic inflammatory response in the systemic system, thus increasing the risk of cancer development. This study intends to determine the extent of air pollution's impact on colorectal cancer prognosis by analysing survival data of colorectal cancer patients in regions with different pollution levels. As well as to investigate the association between air pollution levels and postoperative recurrence in colorectal cancer patients, looking for possible mechanisms.

02

Conditions studied

  • Colorectal Carcinoma

Keywords

  • colorectal cancer
  • environment
  • airpollution
  • greenness
03

In context

Colorectal Neoplasms

5,599 studies on the registry are indexed under Colorectal Neoplasms; 1,459 are open to participants now.

This study's enrollment of 6,300 is above the median of 250 across 1,226 observational studies indexed under Colorectal Neoplasms.

Browse Colorectal Neoplasms studies →

Lead sponsor

Dong Peng is the lead sponsor of 14 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

patients diagnosed as colorectal cancer

Inclusion criteria

  • age ≥18 years;
  • patients diagnosed with colorectal cancer by pathological biopsy before surgery;
  • patients did not undergo chemotherapy, radiotherapy, targeted and immunotherapy, etc. before enrolment;
  • willing to participate in this study and sign an informed consent form;
  • complete clinical data.

Exclusion criteria

Exclusion Criteria:

  • patients with primary malignant tumours other than colorectal cancer;
  • patients with systemic diseases, such as severe cardiopulmonary insufficiency, that affect the choice of treatment options;
  • patients who are not suitable for enrolment as assessed by the investigator;
  • incomplete clinical data.
05

Study design

Observational model
Cohort
Time perspective
Retrospective
Enrollment
6,300 participants (actual)
Patient registry
No

Groups and cohorts

  • the colorectal cancer group

    patients diagnosed as colorectal cancer

06

What researchers measure

Primary outcomes

  1. colorectal cancer

    the time for diagnosing colorectal cancer

    Time frame: From 18 years old until the developing colorectal cancer, through study completion, an average of 5 year.

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No — Clinical centres conducting this study are not allowed to disclose patient information and data sharing.

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Nov 13, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06686953
Lead sponsor
Dong Peng
Responsible party
Dong Peng (Principal Investigator, First Affiliated Hospital of Chongqing Medical University) — Sponsor-investigator
First posted
Nov 13, 2024
Start date
Jan 1, 2010
Primary completion
Nov 1, 2024
Completion
Nov 1, 2024
Last update
Nov 13, 2024

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion